Neuromuscular

Here's some of what is coming soon to NeurologyLive® this week.

Efgartigimod alfa SC is now approved in Europe for patients with chronic inflammatory demyelinating polyneuropathy, following a positive recommendation from the Committee for Medicinal Products for Human Use.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on pediatric neurology.

Biogen recently launched a pivotal phase 3 trial for omaveloxolone, aiming to explore its safety and efficacy in pediatric patients with Friedreich ataxia.

Marketed as the first drug to target both BLyS and APRIL, Telitacicept may offer a revolutionary treatment option for patients with myasthenia gravis.

Researchers uncover a latent infection model for Creutzfeldt-Jakob disease, revealing insights into its mysterious origins and potential triggers.

New long-term data support ecopipam's safety and sustained efficacy in reducing tics and improving quality of life in pediatric Tourette syndrome.

Here's some of what is coming soon to NeurologyLive® this week.

Avidity Biosciences advances del-brax for FSHD, initiating a pivotal Phase 3 study while exploring accelerated FDA approval pathways.

Daniel Mikol, MD, PhD, chief medical officer at NervGen Pharma, provided clinical perspective on recently announced positive findings from a phase 1b/2a trial testing NVG-291 as a treatment for spinal cord injury.

New 5-year findings from the National RLS Opioid Registry presented at SLEEP 2025 highlight the long-term stability and dose trends of low-dose opioid therapy in patients with restless legs syndrome.

Catch up on any of the neurology news headlines you may have missed over the course of May 2025, compiled all into one place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

New data reveals RGX-202 gene therapy shows significant improvements in Duchenne muscular dystrophy patients, enhancing disease management and safety.

Phil Lambert, PhD, chief scientific officer at Satellos Bioscience, discusses the rationale and early clinical progress of SAT-3247, a novel regenerative therapy targeting muscle stem cells in Duchenne muscular dystrophy.

AJ201 shows promising safety and efficacy in treating spinal and bulbar muscular atrophy, marking a potential breakthrough for patients.

Josh Bryson, PhD, head of Medical Affairs at Argenx, discussed the safety profile of efgartigimod in light of recent FAERS-based infection data and offered clinical context for patient care.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network. for the week ending May 31, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 30, 2025.

AHN Saint Vincent Hospital offers advanced neurological care, reducing wait times and providing local access to specialized treatments for various conditions.

Jeff Smith, PhD, chief executive officer at Precision Biosciences, explained the clinical potential and gene-editing mechanism of PBGENE-DMD, a one-time therapy targeting dystrophin mutations in Duchenne muscular dystrophy.

The vice president and franchise lead of Autoimmune at Hansa Biopharma shed insights on imlifidase’s targeted mechanism and promising phase 2 data in treating Guillain-Barré syndrome.

The vice president and franchise lead of Autoimmune at Hansa Biopharma provided clinical insights on latest phase 2 safety and efficacy data on imlifidase, an IgG-cleaving antibody, in Guillain-Barré syndrome. [WATCH TIME: 3 minutes]

Nuvig's NVG-2089 shows promise in CIDP treatment, offering a safer, more efficient alternative to IVIg with a patient-friendly trial design.

BioVie initiates a phase 2 trial for bezisterim, targeting neurological symptoms of Long COVID, aiming to improve patient quality of life.

Here's some of what is coming soon to NeurologyLive® this week.

Investigators explore a phase 4 trial transitioning CIDP patients from IVIg to efgartigimod, aiming to enhance treatment safety and efficacy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 23, 2025.